List view / Grid view
26 February 2016 | By Victoria White
Descovy is an investigational fixed-dose combination for the treatment of HIV-1 infection in adults and adolescents in combination with other HIV antiretroviral agents...
24 February 2016 | By Victoria White
At Week 48 of the study, the F/TAF-based regimens were found to be statistically non-inferior to the F/TDF-based regimens in HIV-1 infected adult patients...
23 February 2016 | By Victoria White
ONCEMRK is evaluating an investigational once-daily formulation of Isentress (raltegravir), known as raltegravir 600 mg, for previously untreated HIV-1 infected adults...
1 February 2016 | By Victoria White
The application is based on the results of two large placebo-controlled trials of Truvada for PrEP, the Pre-Exposure Prophylaxis Initiative (iPrEX) and Partners PrEP...
8 January 2016 | By Victoria White
ViiV Healthcare has formalised its collaboration with Janssen for the Phase III investigation and commercialisation of the injectable formulations of cabotegravir and rilpivirine...
18 December 2015 | By Victoria White
ViiV will pay to Bristol-Myers Squibb upfront payments totaling $350 million with potential development and regulatory milestone payments of up to $518 million for the clinical assets and up to $587 million for the discovery and preclinical programmes...
2 December 2015 | By Victoria White
Johnson & Johnson has announced four new public-private partnerships to significantly reduce the burden of HIV incidence, especially among adolescent girls...
23 November 2015 | By
Genvoya is the first TAF-based regimen to receive marketing authorisation in the EU...
6 November 2015 | By Victoria White
Genvoya contains a new form of tenofovir that has not been previously approved...
3 November 2015 | By Victoria White
Results from the study show that cabotegravir and rilpivirine were comparable in maintaining viral suppression rates to a three drug oral regimen...
26 October 2015 | By Victoria White
If approved by the European Commission, Edurant will become available for the treatment of adolescents with HIV-1 for the first time...
23 October 2015 | By Victoria White
BMS-955176 is a second-generation maturation inhibitor designed to inhibit one of the last steps of the HIV-1 viral lifecycle...
22 October 2015 | By Victoria White
Genvoya was found to be statistically non-inferior to Stribild based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL...
30 September 2015 | By Victoria White
Pregnant women who received the anti-HIV drug in their third trimester gave birth to babies whose bone mineral content was 12% lower than that of infants who were not exposed to the drug...
23 September 2015 | By Victoria White
A Phase IIIb/IV study demonstrated that viral suppression was non-inferior for patients switching to once-daily Triumeq from an antiretroviral therapy...
